Abstract
Signalling from receptor tyrosine kinases is presumably the most investigated pathway so far and myriad of protein components and respective interactions involved have been outlined. Considerably, disconcerted receptor tyrosine kinase signalling has been implicated in the generation and maintenance of many different human diseases. The two crucial interlinked axes in receptor tyrosine kinase signalling have received immense attention as therapeutic targets. One contains the Ras activated Raf kinases and their object kinase cascade, the other involves phosphoinositide 3-kinase (PI3K) and downstream targets like the protein kinase Akt (also known as protein kinase B). The PI3K pathway regulates various cellular functions such as proliferation, survival, migration and metabolism. Small molecule PI3K inhibitors with isoenzyme selectivity have been developed in growing number and used as tools to elucidate the isoenzyme specific functions. The pharmacological inhibitors assayed for potentials as therapeutic agents in the treatment of diseases as diverse as cancer, leukaemia, thrombosis and allergic response in different model systems presented promising and also some unexpected results.
Keywords: phosphoinositide 3-Kinase, isoenzyme, selective, inhibition, receptor tyrosine kinases, insulin signalling, cancer, thrombosis, leukaemia, p110 alpha, p110 beta, p110 gamma, p110 delta, G-protein coupled receptors, Ras, c-Met, PKB/Akt, PTEN, Glycoprotein VI, B cells, AML, ERBB2, cell cycle, embryonic development, mutation
Current Signal Transduction Therapy
Title: Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Volume: 6 Issue: 3
Author(s): Laszlo Buday and Szabolcs Sipeki
Affiliation:
Keywords: phosphoinositide 3-Kinase, isoenzyme, selective, inhibition, receptor tyrosine kinases, insulin signalling, cancer, thrombosis, leukaemia, p110 alpha, p110 beta, p110 gamma, p110 delta, G-protein coupled receptors, Ras, c-Met, PKB/Akt, PTEN, Glycoprotein VI, B cells, AML, ERBB2, cell cycle, embryonic development, mutation
Abstract: Signalling from receptor tyrosine kinases is presumably the most investigated pathway so far and myriad of protein components and respective interactions involved have been outlined. Considerably, disconcerted receptor tyrosine kinase signalling has been implicated in the generation and maintenance of many different human diseases. The two crucial interlinked axes in receptor tyrosine kinase signalling have received immense attention as therapeutic targets. One contains the Ras activated Raf kinases and their object kinase cascade, the other involves phosphoinositide 3-kinase (PI3K) and downstream targets like the protein kinase Akt (also known as protein kinase B). The PI3K pathway regulates various cellular functions such as proliferation, survival, migration and metabolism. Small molecule PI3K inhibitors with isoenzyme selectivity have been developed in growing number and used as tools to elucidate the isoenzyme specific functions. The pharmacological inhibitors assayed for potentials as therapeutic agents in the treatment of diseases as diverse as cancer, leukaemia, thrombosis and allergic response in different model systems presented promising and also some unexpected results.
Export Options
About this article
Cite this article as:
Buday Laszlo and Sipeki Szabolcs, Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?, Current Signal Transduction Therapy 2011; 6 (3) . https://dx.doi.org/10.2174/157436211797484001
DOI https://dx.doi.org/10.2174/157436211797484001 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quercetin Promotes Cell Cycle Arrest and Apoptosis and Attenuates the Proliferation of Human Chronic Myeloid Leukemia Cell Line-K562 Through Interaction with HSPs (70 and 90), MAT2A and FOXM1
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Anti-Cancer Agents in Medicinal Chemistry Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued) Dynamics of CD86 Expression on Allergic Inflammation - New Insights
Recent Patents on Inflammation & Allergy Drug Discovery Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine Invasive Aspergillosis in Children and Adolescents
Current Pharmaceutical Design Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Epidemiology and Prevention of Bacterial Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism “Momordica balsamina: A Medicinal and Neutraceutical Plant for Health care Management”. Comments: Biotechnological Potential of M. balsamina Revealed
Current Pharmaceutical Biotechnology Subject Index to Volume 10
Current Pharmaceutical Design